Clinical Trial Update: CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML or HR-MDS [Phase 1]

View source ↗

Summary

Phase 1 clinical trial of CD64 CAR T cell therapy for adults with relapsed/refractory AML or high-risk MDS. The trial status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• CD64 CAR T-cell therapy

Snippet

Sponsor: University of Colorado, Denver | Conditions: Refractory Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS) | Phase 1 | Status: NOT_YET_RECRUITING